NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03668496,A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC,https://clinicaltrials.gov/study/NCT03668496,,UNKNOWN,"This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study. Target population is patients with stage IV squamous non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to compare the efficacy and safety of SHR-1210 + carboplatin + paclitaxel with placebo + carboplatin + paclitaxel in study population in China. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.",NO,Lung Cancer Squamous Cell|Lung Cancer Stage IV|PD-1 Antibody|Chemotherapy Effect,DRUG: SHR-1210|DRUG: The placebo,"Progression-free survival (PFS), PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the Independent Review Committee according to RECIST v1.1 or death from any cause, whichever occurs first., up to 24 month","Progression-free survival, Progression-free survival (PFS) assessed by investigators according to RECIST V 1.1, up to 24 month|Overall Survival (OS), defined as time from the randomized to the time of the patient's death from any reason assessed by researchers., up to 24 month|Objective Response Rate (ORR), The percentage of patients with CR and PR assessed by investigators according to Recist v 1.1., up to 24 month|disease control rate (DCR), The proportion of patients who have achieved complete response， partial response and Stable disease assessed by investigators according to Recist v 1.1., up to 24 month|Duration of response （DoR）, According to Recist v 1.1 accessed by investigators, up to 24 month|Adverse events (AEs), All adverse event/Serious adverse event that occurred during the study period according to CTCAE v 4.03, up to 24 month",,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,390,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",SHR-1210-III-307,2018-11-09,2020-11-06,2021-12-31,2018-09-12,,2021-03-15,"Anhui Provincial Hospital, Hefei, Anhui, 230036, China|The Second Affiliated Hospital Of Anhui Medical University, Hefei, Anhui, 230036, China|Anhui Chest Hospital, Hefei, Anhui, MD, China|Beijing Cancer Hospital, Beijing, Beijing, 100000, China|The Fifth Medical Center of PLA Ceneral Hospital, Beijing, Beijing, 100000, China|The Seventh Medical Center of PLA Ceneral Hospital, Beijing, Beijing, 100000, China|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Chongqing University Cancer Hospital, Chongqing, Chongqing, 400030, China|900TH Hospital of Joint Logistics Support Force, Fuzhou, Fujian, 350001, China|Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, 510095, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China|Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China|Jieyang People's Hospital, Jieyang, Guangdong, 522000, China|Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563003, China|Affiliated Hospital of Chengde Medical College, Chengde, Hebei, 067000, China|The Fourth Hospital of Hebei Medical University (Hebei Cancer Hospital), Shijiazhuang, Hebei, 50000, China|Tangshan People's Hospital, Tangshan, Hebei, 63001, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150000, China|Henan Cancer Hospital, Zhengzhou, Henan, 450000, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China|Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, China|Hubei Cancer Hospital, Wuhan, Hubei, 430000, China|Tongji Hospital, Tongji Medical College of Hust, Wuhan, Hubei, 430000, China|Xiang yang Central Hospital, Xiangyang, Hubei, 441000, China|Hunan Cancer Hospital, Changsha, Hunan, 410006, China|The Second Xiangya Hospital Of Central South University, Changsha, Hunan, 410008, China|The Third Xiangya Hospital Of Central South University, Changsha, Hunan, 410013, China|Jiangsu Province Hospital, Nanjing, Jiangsu, 210000, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, 210008, China|Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214122, China|Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, 225001, China|Jiangxi Cancer Hospital, Nanchang, Jiangxi, 330006, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130012, China|Jilin Cancer Hospital, Changchun, Jilin, 130012, China|The First Bethune Hospital of Jilin University, Changchun, Jilin, 130012, China|The First Hospital of China Medical University, Shenyang, Liaoning, 110001, China|Jinan Central Hospital, Jinan, Shandong, 250013, China|LinYi Cancer Hospital, Linyi, Shandong, 276001, China|Shanghai Changhai Hospital, Shanghai, Shanghai, 200433, China|Shanghai Pulmonary Hospital, Tongji University, Shanghai, Shanghai, 200433, China|Baoji Central Hospital, Baoji, Shanxi, 721000, China|Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, 046000, China|Shanxi Provincial People's Hospital, Taiyuan, Shanxi, 030000, China|Shaanxi Provincial Cancer Hospital, Xian, Shanxi, 710061, China|Sichuan Provincial Cancer Hospital, Chengdu, Sichuan, 610000, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, 300060, China|Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, 650118, China|The First Affiliated Hospital，ZheJiang University, Hangzhou, Zhejiang, 310003, China|Sir Run Run Shaw Hospital ZheJiang University School Of Medicine, Hangzhou, Zhejiang, 310018, China|ZheJiang Cancer Hospital, HangZhou, Zhejiang, 310022, China|The Second Affiliated Hospital of Zhejiang University of Medicine, Hangzhou, Zhejiang, 310052, China|Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, 317000, China",
